LIVGOTCServices-Prepackaged SoftwareUS GAAP · USD

Livento Group, Inc.

Livento Group, Inc. is a U.S.-based microcap services company built around software and media-related activities, including the Elisee software and BOXO movie production projects. The company appears to operate with a project-based, capital-constrained model that combines software monetization, film-related investments, and related online asset management.

Ask about the company
Revenue0.2m USD
−91.0 %y/y
Operating profit (EBIT)-13.9m USD
−545.6 %y/y
EBIT margin-9,196.8%
−9,069.3 ppy/y
Net income-12.3m USD
−1,965.7 %y/y
Free cash flow0.8m USD
+628.9 %y/y

Fiscal year 2025 · change from previous year

Development 2016–2025

-15-10-505m USD2016: EBIT -9.1 m USD20162021: 2.0 m USD2021: EBIT -0.21 m USD20212022: 2.0 m USD2022: EBIT -0.59 m USD20222023: 2.0 m USD2023: EBIT -6.5 m USD20232024: 1.7 m USD2024: EBIT -2.2 m USD20242025: 0.15 m USD2025: EBIT -14 m USD20250.15-14
RevenueOperating profit (EBIT)
Ask Clarifo about Livento Group, Inc.

Business

Share of revenue
Software assets50 %

Includes the Elisee and Novelti software products that the company seeks to monetize through rental or related commercial use.

Film and media projects35 %

Project-based movie production activities under the BOXO umbrella that require outside investor funding.

Asset rental and licensing15 %

Revenue tied to renting or otherwise monetizing software and media-related assets.

Customers

The company’s customers appear to be a mix of investors, project participants, and users or licensees of its software assets. Its film projects depend on outside capital providers, while software monetization likely targets counterparties seeking access to the Elisee and Novelti platforms or related rights.

Project investors

Provide capital for BOXO movie projects and expect project-level participation or returns.

Software users/licensees

Buy access to or usage rights for Elisee and Novelti software assets.

Production collaborators

Directors, actors, and other participants engaged when film projects are funded.

Asset rental counterparties

Pay to rent or otherwise monetize software and movie-related assets.

Strategy

The company’s stated direction is to fund and execute software and movie projects while improving access to capital and market visibility. Management also appears focused on keeping projects funded, monetizing existing assets, and moving toward a more tradable public-market status.

Capital raisingShort term

The business model depends on external funding to support operations and project investment.

Asset monetizationShort term

Software and movie assets must generate rent or usage revenue to support the company.

Market access and listing improvementMedium term

Better trading status could improve liquidity and help future capital formation.

Geography

Livento Group is headquartered in the United States and appears to conduct most of its business from a U.S. base. The available excerpts do not disclose a meaningful country-by-country revenue split, so geographic exposure is best viewed as concentrated in the U.S. with potential project-level reach depending on film and software counterparties.

Risks

Livento is exposed to acute financing risk because its operations and project pipeline depend on outside capital and it has reported very limited cash. The company also faces execution risk in capital-intensive movie production, cybersecurity risk for online software assets, and liquidity risk from delayed customer payments and penny-stock trading constraints.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Capital shortfall1Project execution risk in film production2Liquidity and market access3Customer payment timing4Cybersecurity5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Capital shortfallImpact: HighLikelihood: High

    The company states it may not be able to raise additional capital needed for operations and growth.

    Exposure: Operations and project funding

  2. Project execution risk in film productionImpact: HighLikelihood: High

    BOXO projects are capital intensive and require continued participation from many parties.

    Exposure: Movie production pipeline

  3. Liquidity and market accessImpact: MediumLikelihood: High

    Pink Sheets / penny stock trading can reduce liquidity and make capital raising harder.

    Exposure: Common stock trading and financing

  4. Customer payment timingImpact: MediumLikelihood: High

    Delayed or failed payments from clients can create cash flow problems and affect liabilities.

    Exposure: Working capital

  5. CybersecurityImpact: MediumLikelihood: Low

    Movie projects and Elisee software are stored online and could be exposed to cyber threats.

    Exposure: Cloud-hosted assets and data

Ask Clarifo about Livento Group, Inc.

Accounting

Judgemental items
Amortization

Management says amortization contributed to the reported loss, so asset lives and expense timing matter.

Impact: Affects operating results and carrying values

Stock-based compensation

The company cites stock-based compensation as a factor in losses, which can distort cash-based performance.

Impact: Affects net income and comparability

Asset impairment and valuation

Software and movie-related assets may need impairment testing if monetization falls short.

Impact: Could reduce asset values and earnings

Revenue recognition

Rental or project-based income may depend on contract terms and timing of delivery or use.

Impact: Can shift revenue between periods

Similar listed companies

Publicly listed companies with a comparable business focus.

Winvest Group Ltd

WNLV · Services-Motion Picture & Video Tape Production

Starguide Group, Inc.

STRG · Wholesale-Miscellaneous Nondurable Goods

Pony Group Inc.

PNYG · Services-Automotive Repair, Services & Parking

Lucent, Inc.

LUCN · Services-Business Services, NEC

Liberty Live Holdings, Inc.

LLYVA · Services-Amusement & Recreation Services

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026